Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gene Therapy using Intramuscular Administration of AMG0001 in Patients with Peripheral Arterial Disease

Next Previous
Trial Profile

Gene Therapy using Intramuscular Administration of AMG0001 in Patients with Peripheral Arterial Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Beperminogene perplasmid (Primary)
  • Indications Arteriosclerosis obliterans; Chronic limb-threatening ischemia; Thromboangiitis obliterans
  • Focus Therapeutic Use

    • Most Recent Events

    • 23 Sep 2020 Status changed from active, no longer recruiting to completed.
    • 22 Jan 2018 According to a AnGes MG media release, the company anticipates being granted conditional approval under the regulatory scheme of Approval with Conditions and Time Limit for regenerative medicines. The review process is expected to take approximately one year.
    • 22 Jan 2018 According to a AnGes MG media release, based on the positive results from the phase III trial (UMIN000000730) and this investigator-led clinical study (UMIN000014918) conducted in Japan, an application for marketing approval of HGF plasmid for the treatment of critical limb ischemia (CLI), the most severe condition of peripheral arterial disease, has been submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top